Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat reports. Eleven equities research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $64.44.

JSPR has been the subject of several recent analyst reports. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. UBS Group initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 target price for the company. HC Wainwright lowered their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company.

Jasper Therapeutics Stock Down 3.1 %

Shares of NASDAQ JSPR opened at $5.97 on Thursday. The firm has a 50-day simple moving average of $11.23 and a 200-day simple moving average of $17.13. The stock has a market capitalization of $89.52 million, a price-to-earnings ratio of -1.26 and a beta of 2.11. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01.

Hedge Funds Weigh In On Jasper Therapeutics

Large investors have recently bought and sold shares of the company. Soleus Capital Management L.P. grew its stake in shares of Jasper Therapeutics by 11.2% during the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock worth $31,951,000 after purchasing an additional 150,755 shares during the period. Tema Etfs LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $266,000. Stempoint Capital LP acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $2,892,000. Integral Health Asset Management LLC grew its stake in shares of Jasper Therapeutics by 85.7% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after purchasing an additional 300,000 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $668,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.